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A B S T R A C T
Purpose
The differential diagnosis among the commonest peripheral T-cell lymphomas (PTCLs; ie, PTCL
not otherwise specified [NOS], angioimmunoblastic T-cell lymphoma [AITL], and anaplastic
large-cell lymphoma [ALCL]) is difficult, with the morphologic and phenotypic features largely
overlapping. We performed a phase III diagnostic accuracy study to test the ability of gene
expression profiles (GEPs; index test) to identify PTCL subtype.
Methods
We studied 244 PTCLs, including 158 PTCLs NOS, 63 AITLs, and 23 ALK-negative ALCLs. The
GEP-based classification method was established on a support vector machine algorithm, and the
reference standard was an expert pathologic diagnosis according to WHO classification.
Results
First, we identified molecular signatures (molecular classifier [MC]) discriminating either AITL and
ALK-negative ALCL from PTCL NOS in a training set. Of note, the MC was developed in
formalin-fixed paraffin-embedded (FFPE) samples and validated in both FFPE and frozen tissues.
Second, we found that the overall accuracy of the MC was remarkable: 98% to 77% for AITL and
98% to 93% for ALK-negative ALCL in test and validation sets of patient cases, respectively.
Furthermore, we found that the MC significantly improved the prognostic stratification of patients
with PTCL. Particularly, it enhanced the distinction of ALK-negative ALCL from PTCL NOS,
especially from some CD30 PTCL NOS with uncertain morphology. Finally, MC discriminated
some T-follicular helper (Tfh) PTCL NOS from AITL, providing further evidence that a group of
PTCLs NOS shares a Tfh derivation with but is distinct from AITL.
Conclusion
Our findings support the usage of an MC as additional tool in the diagnostic workup of nodal PTCL.
J Clin Oncol 31:3019-3025. © 2013 by American Society of Clinical Oncology
INTRODUCTION
Peripheral T-cell lymphomas (PTCLs) represent
10%to15%of all lymphomas, and their incidence is
higher in Asia than inWestern countries.1 They in-
clude several different entities1; however, four main
subtypes (ie, PTCL not otherwise specified [NOS],
angioimmunoblastic T-cell lymphoma [AITL], and
anaplastic large-cell lymphoma [ALCL; ALK nega-
tive and ALK positive]) represent approximately
75% of all patient cases in Europe and the United
States.1 The diagnosis of PTCL is usually challeng-
ing, requiring expertise in hematopathology. In this
regard, a large international study recently reported
that up to 30% of PTCLs are misdiagnosed.2 Addi-
tionally, the differential diagnosis among nodal PT-
CLsmaybeaffectedby subjective criteria. In fact, the
morphology and phenotype of PTCL NOS is quite
variable, the former including features usually ob-
served in AITL or ALCL (ie, clear follicular T-
helper–related or large CD30 cells, respectively).
Moreover, only a fraction of ALCLs carry a specific
genetic lesion—t(2;5) and variants, all leading to
ALKaberrant expression—defining adistinct entity
in WHO classification. However, the distinction of
PTCL NOS from either AITL or ALK-negative
ALCL is not trivial. In fact, ALK-negative ALCL and
PTCLNOS are characterized by a different progno-
sis,3 and distinct therapeutic approaches have
been proposed.4
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Recently, geneexpressionprofiling (GEP)was showntobeuseful
to discriminate different entities when morphology and phenotype
are not consistent.5,6 In this regard, some reports have described the
ability of GEP in differentiating PTCL NOS from ALCL or AITL.7-11
However, these studiesusedRNAfromfresh/frozen samples andwere
not designed to test the diagnostic value of molecular signatures.
In this phase III study, we aimed first to test the diagnostic
accuracy of GEP-based molecular classifiers (MCs) in the differential
diagnosis between PTCL NOS and either AITL or ALK-negative
ALCL, starting from formalin-fixed paraffin-embedded (FFPE) tis-
sues, and second to evaluate the potential clinical implications.
METHODS
Patient Case Selection
We studied 244 nodal PTCLs, starting from either FFPE (n  112) or
fresh/frozen (n 132) tissues. We included samples of PTCLNOS (n 80),
AITL (n 20), andALK-negativeALCL (n 12) forwhichFFPEblockswere
available, and patients had given permission for analysis.
In addition, we studied 132 PTCLs (78 PTCLs NOS, 43 AITLs, and 11
ALK-negative ALCLs) as a validation set for which GEP had been previously
generated from fresh/frozen biopsies by our group7-10 (Gene ExpressionOm-
nibus data setsGSE6338 andGSE19069). The latter did not correspond to any
of the FFPE samples, having been recruited in a previous national study.7
Additional details are provided in the Data Supplement.
GEP Generation and Analysis
After RNA extraction, cDNA was prepared per manufacturer instruc-
tions, and gene expression analysis was carried out as previously re-
ported,7,12,13 according to MIAME (Minimum Information About a
MicroarrayExperiment) guidelines.Rawgeneexpressiondatawill be available
online after publication14 (details provided in Data Supplement).
Diagnostic Accuracy Evaluation
We tested the ability of two molecular signatures to discriminate either
AITL or ALK-negative ALCL from PTCL NOS, respectively. Calculation of
sensitivity (ST), specificity (SP), positive predictive value (PPV), negative
predictive value (NPV), positive and negative likelihood ratio (LR), and odd
ratio was performed using CATmaker software (Centre for Evidence-Based
Medicine, Oxford University, Oxford, United Kingdom; http://www.cebm
.net). The study was designed and conducted according to the STARD (Stan-
dards for the Reporting of Diagnostic Accuracy Studies) statement15 and
REMARK(ReportingRecommendations forTumorMarkerPrognosticStud-
ies) guidelines16 and informed by theQUADAS (Quality Assessment ofDiag-
nostic Accuracy Studies) model.17 In particular, all patient cases were
evaluated with both index (GEP-based classifier) and reference tests (histopa-
thology, includingcomplete immunohistochemistry, according toWHOclas-
sification),18 the twomethods being completely independent.
Survival Analyses
Clinical information and complete follow-up were available for 203 of
244patient cases. Specifically, overall survival (OS)wascalculated fromtimeof
diagnosis to death or last follow-up. Statistical analyses were carried out using
IBM SPSS Statistics 20.0 (IBM, Armonk, NY). Survival data were analyzed
using the Kaplan-Meier and log-rank Mantle-Cox methods.19 The limit of
significance for all analyses was defined as P .05.
RESULTS
AITL and ALK-Negative ALCL Can Be Distinguished
From PTCL NOS Based on Global GEP
Because unsupervised algorithms failed to clearly distinguish
PTCL subtype (Data Supplement), we performed a supervised com-
parisonofPTCLNOSandeitherAITLorALCL(t testwithBonferroni
post hoc correction and Mann-Whitney test with Benjamini-
Hochberg post hoc correction, respectively) using a training set of
FFPE samples (25 PTCLs NOS, 10 AITLs, and six ALK-negative
ALCLs). Indeed, basing onP value (P .05) and fold change ( 2),
we identified genes differentially expressed. In particular, we found
208 genes distinguishing PTCL NOS from AITL and 1,133 distin-
guishing PTCL/NOS from ALK-negative ALCL (Figs 1A and 1B;
Data Supplement).
Subsequently,weperformedapathwayanalysis to assesswhether
the identified signatures corresponded to specific biologic functions.
Remarkably, we found that genes distinguishing the different PTCLs
were involved in relevant cellular programs. Specifically, genes dis-
criminatingPTCL/NOS fromAITLwereparticularly involved in lipid
metabolism, DNA replication, and regulation of cell cycle (Data Sup-
plement). On the other hand, genes differentially expressed in PTCL/
NOS versus ALK-negative ALCL were significantly involved in
regulationof apoptosis, proteinkinase cascade, and immune response
(Data Supplement).
Afterward, we investigated whether the identifiedmolecular sig-
natures could correctly distinguish AITL and ALK-negative ALCL
samples fromPTCLNOSby studying an independent test set of FFPE
samples (55 PTCLs NOS, 10 AITLs, and six ALK-negative ALCL
patient cases). Of note, by applying a hierarchic clustering, the differ-
ent diseaseswere definitely discriminated (AITL vPTCLNOS,2P
.001;ALK-negativeALCL vPTCLNOS,2P .001; Figs 1Cand1D).
Analog results were obtained in the validation set of fresh/frozen
samples (Data Supplement).
GEP-Based MC Is Efficient in Discriminating AITL and
ALK-Negative ALCL From PTCL NOS
We then focused on the possibility of developing a practical tool
that could be applied in the routine diagnostic workup for the differ-
ential diagnosis of nodal PTCLs. To address this issue, we used a
support vector machine algorithm, an easily reproducible system for
GEP data management. First, we built the model by using all signa-
tures in the training setofpatient cases (25PTCLsNOS,10AITLs, and
six ALK-negative ALCLs) and then challenged it in the test set of
patient cases (55 PTCLs NOS, 10 AITLs, and six ALK-negative
ALCLs). Indeed, by applying the AITL prediction model, it was pos-
sible to correctly classify nine of 10 AITLs and 55 of 55 PTCLs NOS,
with ST and SPof 90%and 100%, respectively. Accordingly, PPV and
NPV were calculated as 100% and 98%, respectively, for an overall
accuracy of 98% (Table 1; Data Supplement).
Alternatively, when we applied the ALK-negative ALCL predic-
tion model, six of six ALCLs and 54 of 55 PTCLs NOS were correctly
classified, with ST and SP of 100% and 98%, respectively. PPV and
NPV were then calculated as 86% and 100%, respectively, for an
overall accuracy of 98% (Table 2; Data Supplement).
We then tested the ability of MCs based on a more limited
number of genes. Of note, by discriminant analysis, we could restrict
the number of genes of the MC to 38 and 53 for AITL and ALK-
negative ALCL, respectively, while maintaining the same accuracy.
Because these results seemed to have potential clinical relevance,
tomake our datamore robust, we further tested the value of the assay
in an independent data set (validation set) consisting of 78 PTCLs
NOS, 43 AITLs and 11 ALK-negative ALCLs. Of note, these patient
caseswereoriginally studied starting fromfresh/frozenmaterialwith a
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different microarray; therefore, our analysis also served as additional
technical control on the efficiency of the DASL (cDNA-Mediated
Annealing, Selection, Extension, andLigation) assay. In this case, with
the AITL predictionmodel, 31 of 43 AITLs and 62 of 78 PTCLs NOS
were correctly classified,withSTandSPof72%and80%, respectively.
Accordingly, PPV and NPV were 66% and 84%, respectively, for an
overall diagnostic accuracy of 77% (Table 3; Data Supplement). Sim-
ilarly, when PTCLNOSwas tested against ALK-negative ALCL, eight
of 11 ALCLs and 75 of 78 PTCLs NOS were correctly classified, with
ST and SP of 73% and 96%, respectively. Therefore, PPV and NPV
were then calculated as 73% and 96%, respectively, for an overall
diagnostic accuracy of 93% (Table 4; Data Supplement). Together,
these results indicate a remarkable diagnostic accuracy for the GEP-
based MC in discriminating AITL and ALK-negative ALCL from
PTCLNOS.
MCs Significantly Affect Post-Test Probability
of Disease
Because a major factor in the indication of medical tests is their
ability tomake a difference between pre- andpost-test probabilities of
a given condition, we tested our MCs in this sense. Remarkably,
concerning thediscriminationofAITL fromPTCLNOS, thepost-test
probability was increased from 15% to 100% and reduced from 15%
to 2% for positive and negative results, respectively, in the test set.
BA
DC
AITL
PTCL/NOS
-5.8 5.80
ALK-negative ALCL
PTCL/NOS
-5.8 5.80
ALK-negative ALCL
PTCL/NOS
AITL
PTCL/NOS χ2 P < .001
χ2 P < .001
-6.2 6.20-5.5 5.50
Fig 1. Supervised analyses identified
genes differentially expressed in (A) angio-
immunoblastic T-cell lymphoma (AITL)
versus peripheral T-cell lymphoma (PTCL)
not otherwise specified (NOS) and (B)
ALK-negative anaplastic large-cell lym-
phoma (ALCL) versus PTCL (two-tailed t
test P  .05; fold change  2). Top 200
genes in ranking are plotted. Unsuper-
vised hierarchic clustering of nodal PTCLs
constituting test set of patient cases
based on genes differentially expressed in
training set of (C) AITL versus PTCL NOS
and (D) ALK-negative ALCL versus PTCL
NOS (two-tailed t test P  .05; fold
change  2). Top genes emerging from
stepwise discriminant analysis are plot-
ted. In matrix, each column represents
sample, each row represents gene. Color
scale bar shows relative gene expression
changes normalized by standard deviation
(0 is mean expression level of given gene).
Clustering clearly distinguished AITL (2
P  .001) and ALK-negative ALCL from
PTCL NOS (2 P  .001).
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Similarly, it changed from 35% to 66% and to 16% for positive and
negative results, respectively, in the validation set. Regarding the iden-
tification of ALK-negative ALCL, post-test probability was increased
from 10% to 86% and reduced from 10% to 1% for positive and
negative results, respectively, in the test set. Similarly, it moved from
12% to 72% and to 4% for positive and negative results, respectively,
in the validation set (Data Supplement).
MC Improves Categorization and Prognosis of PTCL
Wethen tested thepotential nosologic and clinical impacts of the
MC.Todothis,wefirst applied themodel toapanelof sixPTCLsNOS
with T-follicular helper (Tfh) phenotype but lacking a morphology
consistent with either AITL or PTCLNOS follicular variant. Notably,
all six patient caseswere predicted tobePTCLNOS, providing further
evidence that a subset of PTCL NOS shares a Tfh derivation but is
distinct fromAITL.
Furthermore, we evaluated the impact of theMC in PTCL prog-
nostication.We included 203 of 244 patient cases for which complete
information was available; median follow-up of living patients was
1,088 days (range, 14 to 4,664 days). The median OS for the entire
Table 1. Diagnostic Accuracy of AITL Molecular Classifier Evaluated
in Test Set
GEP
Histopathology
AITL PTCL NOS
AITL 9 0
PTCL NOS 1 55
Accuracy
Histopathology
Value (%) 95% CI
ST 90 71 to 100
SP 100 100 to 100
PPV 100 100 to 100
NPV 98 95 to 100
LR
Positive NC NC
Negative 0.1 0.02 to 0.64
Overall accuracy 98
Pretest probability 15 7 to 24
Abbreviations: AITL, angioimmunoblastic T-cell lymphoma; GEP, gene expression
profile; LR, likelihood ratio; NC, not calculable (tends to infinitum); NOS, not otherwise
specified; NPV, negative predictive value; PPV, positive predictive value; PTCL,
peripheral T-cell lymphoma; SP, specificity; ST, sensitivity.
64 of 65.
Table 2. Diagnostic Accuracy of ALK-Negative ALCL Molecular Classifier
Evaluated in Test Set
GEP
Histopathology
ALK-Negative ALCL PTCL NOS
ALK-negative ALCL 6 1
PTCL NOS 0 54
Accuracy
Histopathology
Value (%) 95% CI
ST 100 100 to 100
SP 98 95 to 100
PPV 86 60 to 100
NPV 100 100 to 100
LR
Positive 55 7.89 to 383.54
Negative NC NC
Overall accuracy 98
Pretest probability 10 2 to 17
Abbreviations: ALCL, anaplastic large-cell lymphoma; GEP, gene expression
profile; LR, likelihood ratio; NC, not calculable (tends to zero); NOS, not
otherwise specified; NPV, negative predictive value; PPV, positive predictive
value; PTCL, peripheral T-cell lymphoma; SP, specificity; ST, sensitivity.
60 of 61.
Table 3. Diagnostic Accuracy of AITL Molecular Classifier Evaluated in
Validation Set
GEP
Histopathology
AITL PTCL NOS
AITL 31 16
PTCL NOS 12 62
Accuracy
Histopathology
Value (%) 95% CI
ST 72.09 59 to 85
SP 79.49 71 to 88
PPV 65.96 52 to 80
NPV 83.78 75 to 92
LR
Positive 3.51 2.19 to 5.65
Negative 0.35 0.21 to 0.58
Overall accuracy 77
Pretest probability 35 27 to 44
Abbreviations: AITL, angioimmunoblastic T-cell lymphoma; GEP, gene
expression profile; LR, likelihood ratio; NC, not calculable (tends to
infinitum); NOS, not otherwise specified; NPV, negative predictive value;
PPV, positive predictive value; PTCL, peripheral T-cell lymphoma; SP,
specificity; ST, sensitivity.
93 of 121.
Table 4. Diagnostic Accuracy of ALK-Negative ALCL Molecular Classifier
Evaluated in Validation Set
GEP
Histopathology
ALK-Negative ALCL PTCL NOS
ALK-negative ALCL 8 3
PTCL NOS 3 75
Accuracy
Histopathology
Value (%) 95% CI
ST 72.73 46 to 99
SP 96.15 92 to 100
PPV 72.73 46 to 99
NPV 96.15 92 to 100
LR
Positive 18.91 5.89 to 60.75
Negative 0.28 0.11 to 0.75
Overall accuracy 93
Pretest probability 12.36 6 to 19
Abbreviations: ALCL, anaplastic large-cell lymphoma; GEP, gene expression
profile; LR, likelihood ratio; NC, not calculable (tends to zero); NOS, not
otherwise specified; NPV, negative predictive value; PPV, positive predictive
value; PTCL, peripheral T-cell lymphoma; SP, specificity; ST, sensitivity.
83 of 89.
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populationwas469days; 3-yearOSrateswere16%,44%, and19%for
patients with AITL, ALK-negative ALCL, and PTCL NOS, respec-
tively. We then calculated the OS curves for patient cases classified
according to either conventional histopathologyorGEP.Remarkably,
although with conventional methods we only observed a trend in
favor of ALK-negative ALCL versus PTCL NOS (median OS, 1,484 v
395days;P .62;Fig2A),whenpatient caseswere reclassifiedbyGEP,
the survival difference between these two groups became statistically
significant (median OS, 1,570 v 391 days; P .011; Fig 2B). On the
contrary, no differences in survival were noted when PTCLNOS was
compared with AITL. Moreover, we tested 14 patient cases of PTCL
with strong CD30 expression but lack of typical ALCL morphology,
for which a consensus histopathologic diagnosis could not be reached
between PTCL NOS and ALK-negative ALCL. All patient cases were
classifiedasPTCLNOS(DataSupplement).Most importantly, theOS
of these patients (10 of 14 were evaluable) turned out to be signifi-
cantly worse than that of patients with ALK-negative ALCL (median
OS, 1,570 v 333 days;P .02; Fig 2C), indicating the usefulness of the
tool in this peculiar setting as well. Details are provided in the Data
Supplement. Together, these data demonstrate the clinical utility of
the proposed tools.
DISCUSSION
In this article, we describe the use of GEP for the differential diagnosis
of the commonest nodal PTCLs by focusing on the distinction of
eitherAITLorALK-negativeALCLfromPTCLNOS,whichmaybeof
remarkable clinical interest and not always clear cut based on WHO
classification criteria.18 Specifically, themorphologic features of AITL
(clear-cell cytology, follicular dendritic cell meshwork, and abundant
arborized high endothelium venules) are matters of subjective evalu-
ation and can be partly observed in some PTCLs NOS.20,21 Further-
more, a proportionof PTCLsNOSpresentwith the typical phenotype
of AITL cells, reflecting their correspondence to normal Tfh lympho-
cytes (CD4, CXCL13, ICOS, PD1, CD10 and CD10, and
BCL6 and BCL6).9,20,22,23 In this regard, we offer objective evi-
dence that such tumors, although sharing the cellular counterpart, do
not correspond toAITL. This finding suggests that a novel category of
Tfh-related PTCLsmight be recognized in the future. Importantly, in
the last fewmonths, somaticmutationsof IDH2andTET2were found
to be associated with AITL, the latter also observed in Tfh PTCL
NOS.24,25 Additionally, Feldman et al26 identified t(6;7)(p25.3;q32.3)
as a specific lesion of ALCL. Therefore, although occurring only in a
fraction of patient cases, their detection can certainly strengthen diag-
nosis of the different PTCL subtypes. Furthermore, PTCLsmay pres-
ent with numerous large cells and CD30 expression,20 making the
differential diagnosis between PTCL NOS and ALK-negative ALCL
problematic. In our series, GEP was able to discriminate AITL and
ALK-negative ALCL from PTCL NOS with remarkable efficiency,
with overall diagnostic accuracy varying from 77% to 98%. Notably,
PPV andNPVwere also significant, with each test resulting in at least
86%foroneof thevalues.Ofnote,whenweevaluated the abilityof the
MCs to make a difference between pre- and post-test patient proba-
bilities of having the given disease (ie, real potential for clinical appli-
cation), we found that they were highly effective (Data Supplement).
Particularly, both the classifiers, having high SP (80% to 100%),
turned out to be good as confirmatory tests or SPIN (Specificity Rule
In) tests (ie, if positive, they confirmpresence of condition). Similarly,
withSTvalues ranging from72%to100%, theyalsoperformedwell as
screening tests or SNOUT (Sensitivity Rule Out) tests (ie, if negative,
they rule out disease).
Indeed, thisphase IIIdiagnostic accuracy study represents, toour
knowledge, a unique example available in this field. Previously, a few
studies in the last years dealt with GEP of PTCL, providing the basic
evidence that different entities could be distinguished based on their
specific GEP. In particular, Martinez-Delgado et al27 showed that
0
Cu
m
ul
at
iv
e 
Su
rv
iv
al
 
(p
ro
ba
bi
lit
y)
Time (days)
1.0
0.8
0.6
0.4
0.2
1,000 2,000 3,000 4,000 5,000 6,000
AITL
ALK-
NOS
AITL censored
ALK- censored
NOS censored
A
0
Cu
m
ul
at
iv
e 
Su
rv
iv
al
 
(p
ro
ba
bi
lit
y)
Time (days)
1.0
0.8
0.6
0.4
0.2
1,000 2,000 3,000 4,000 5,000 6,000
AITL
ALK-
NOS
AITL censored
ALK- censored
NOS censored
B
ALK-
CD30+
ALK- censored
CD30+ censored
0
Cu
m
ul
at
iv
e 
Su
rv
iv
al
 
(p
ro
ba
bi
lit
y)
Time (days)
1.0
0.8
0.6
0.4
0.2
500 1,5001,000 2,000
C
Fig 2. Survival curves according to peripheral T-cell lymphoma (PTCL): (A)
histopathologic subtype, (B) molecular subtype, and (C) molecular distinction of
CD30 PTCL not otherwise specified (NOS) and ALK-negative anaplastic large-
cell lymphoma (ALK-). AITL, angioimmunoblastic T-cell lymphoma.
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PTCL differed fromT-lymphoblastic lymphoma. Subsequently, Ball-
ester et al28 indicated that AITL andALCL could be separate from the
other subtypes, although PTCLs/NOS still remained mixed up. Fi-
nally, Piccaluga et al,7,8 de Leval et al,9 Iqbal et al,10 and Piva et al11
showed that PTCL NOS, AITL, and ALK-negative ALCL could be
discriminated based on theirGEP.7-11 Together, these studies demon-
strated that the different PTCL subtypes retained molecular differ-
ences thatmightbeused for theirdifferential diagnosis.However, they
did not test potential diagnostic accuracy. In addition, prognostic
impact was limited to the distinction of cytotoxic versus helper PTCL
NOS7-10 and to the description of a proliferation signature associated
with worse outcome, this being in line with immunohistochemi-
cal evidence.29,30
Conversely, we developed an MC able to improve the current
stratification of patients with PTCL based on conventional histopa-
thologywith remarkable prognostic impact. In fact, using theMC,we
could distinguish patient caseswith significantly different clinical out-
comes. Additionally, we had the opportunity to study a series CD30
PTCL patient cases, the diagnosis of which was matter of debate
amongexperiencedhematopathologists. Strikingly, theclassifier iden-
tified all of them as PTCLs NOS, not ALCLs. This distinction was not
trivial. In fact, using GEP, we could discriminate a group of CD30
PTCLs NOS with significantly worse outcomes than ALK-negative
ALCLs. Importantly, the inclusion of CD30 forms within PTCL
NOS rather thanwithin ALCL is still largely discussed in the scientific
community. Here, we provide for the first time to our knowledge
objective evidence that CD30 PTCL NOS is distinct from ALK-
negative ALCL, with the two diseases characterized by significantly
different prognoses.
Notably, on the basis of gene ontology enrichment analysis, we
did not have evidence supporting the role of tumor content in the
signature generation. Of course, we cannot exclude aminimal impact
on single-gene expression. However, the validation of the signatures
across three different data setsmakes any significant effect of aspecific
components extremely unlikely. Furthermore, we could rule out a
possible puzzling effect of the microenvironment on class prediction
in all patient cases for which diagnostic material was still available. It
should be underlined that the tool was designed for the routine diag-
nostic use, and theFFPE samples included abundant reactive cells that
were correctly classified.
Interestingly, in this study, we applied a novel microarray tech-
nology able to generate GEP fromFFPE routine tissues.31 Of note, we
obtained a consistent profile in all patient cases examined. Indeed, this
is clinically relevant. In fact,GEPhas failed so far tobecomean integral
part of diagnostic hematopathology, remaining limited to the field of
research, largely because of the need for fresh/frozen material, often
not available in the routine setting. Certainly, DASL whole-genome
GEP can be reliably performed on both fresh and FFPE tissues, using
low amounts of RNA.31 Of note, we were able to confirm the consis-
tency of this tool in a large panel of B- and T-cell lymphomas by
matching gene and protein expression (data not shown), as other
groups have done.32 In addition, we showed that themolecular signa-
tures identified in this study could be successfully applied in an inde-
pendent validation set of patients cases for which GEP was generated
from frozen tissues with different platforms (Illumina, SanDiego, CA
v Affymetrix, Santa Clara, CA). On the other hand, signatures gener-
ated on fresh/frozen samples were successfully applied to our series
(Data Supplement).
Although the studydesign (phase III)doesnot allowan index test
to overcome the reference standard by definition, the proposed clas-
sifiers performed well. Our findings support the use of an MC as an
additional tool in the diagnostic workup of nodal PTCLs. In fact, the
aim of our study was to provide pathologists with another robust
diagnostic tool integrating morphology and phenotype. Bearing this
in mind, it is noteworthy that we were able to significantly limit the
number of genes used for an efficient classification, thus making it
possible to quickly define a customassay specific to this issue, efficient
in FFPE samples. In conclusion, our study identified gene signatures
able to efficiently differentiate nodal PTCLs, starting from FFPE tis-
sues, which may become useful tools in the diagnostic workup of
these diseases.
BolognaUniversity obtained apatent from the ItalianPatent and
TrademarkOffice for themolecular signatures used for the diagnostic
classifier (patent No. 61.U2164.12.IT.34).
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